Osterborg, A <br/><br/>
Clonal CD8+ and CD52- T cells are induced in responding B cell lymphoma patients treated with Campath-1H (anti-CD52).  [electronic resource] 

 -  European journal of haematology  Jan 1997 
 - 5-13 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>0902-4441 
<br/><br/><label>Standard No.: </label>10.1111/j.1600-0609.1997.tb01403.x  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Alemtuzumab<br/>Antibodies, Monoclonal--therapeutic use<br/>Antibodies, Monoclonal, Humanized<br/>Antibodies, Neoplasm--therapeutic use<br/>Antigens, CD--immunology<br/>Antigens, Neoplasm<br/>Antineoplastic Agents--therapeutic use<br/>B-Lymphocytes--immunology<br/>CD52 Antigen<br/>CD8-Positive T-Lymphocytes--immunology<br/>Female<br/>Glycoproteins<br/>Humans<br/>Immunity, Cellular--drug effects<br/>Leukemia, Lymphocytic, Chronic, B-Cell--drug therapy<br/>Lymphoma, Non-Hodgkin--drug therapy<br/>Male<br/>Middle Aged<br/>T-Lymphocyte Subsets--immunology